{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:10:44Z","timestamp":1790892644860,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["This is an investigator-initiated study which rece"],"award-info":[{"award-number":["This is an investigator-initiated study which rece"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1136\/annrheumdis-2018-213902","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T12:16:27Z","timestamp":1539260187000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial"],"prefix":"10.1016","volume":"78","author":[{"given":"Petra","family":"Hissink Muller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M C","family":"Brinkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieneke","family":"Schonenberg-Meinema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytse Bastiaan","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Koopman-Keemink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel C J","family":"Brederije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W","family":"Bekkering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taco W","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette WA","family":"van Suijlekom-Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Merlijn","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Boehringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia F","family":"Allaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2018-213902_bib1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2018-213902_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2018-213902_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/1546-0096-12-13","article-title":"Treatment of juvenile idiopathic arthritis: a revolution in care","volume":"12","author":"Stoll","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1136\/annrheumdis-2018-213902_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","article-title":"Management of juvenile idiopathic arthritis: hitting the target","volume":"11","author":"Hinze","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213902_bib5","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/kep144","article-title":"Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations","volume":"48","author":"Ringold","year":"2009","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2018-213902_bib6","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/art.21389","article-title":"Patterns of clinical remission in select categories of juvenile idiopathic arthritis","volume":"52","author":"Wallace","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4 Suppl 73","key":"10.1136\/annrheumdis-2018-213902_bib7","first-page":"S157","article-title":"Toward a treat-to-target approach in the management of juvenile idiopathic arthritis","volume":"30","author":"Consolaro","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213902_bib8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/ard.2010.133033","article-title":"Juvenile idiopathic arthritis: state of the art and future perspectives","volume":"69","author":"Martini","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6 Suppl 43","key":"10.1136\/annrheumdis-2018-213902_bib9","first-page":"S105","article-title":"Remission in juvenile idiopathic arthritis","volume":"24","author":"Ravelli","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213902_bib10","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213902_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/BOR.0b013e32832f142e","article-title":"Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders","volume":"21","author":"Woo","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213902_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213902_bib13","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/ard.2006.064717","article-title":"Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment","volume":"66","author":"van Rossum","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213902_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.24087","article-title":"Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis","volume":"61","author":"Albers","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213902_bib15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/ard.2008.101030","article-title":"When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213902_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/acr.22477","article-title":"Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy","volume":"67","author":"Chang","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2018-213902_bib17","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/art.30502","article-title":"Clinical outcomes after withdrawal of anti-tumor necrosis factor \u03b1 therapy in patients with juvenile idiopathic arthritis: a twelve-year experience","volume":"63","author":"Baszis","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213902_bib18","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2010.375","article-title":"Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial","volume":"303","author":"Foell","year":"2010","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2018-213902_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/ard.2003.005686","article-title":"Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?","volume":"63","author":"Foell","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213902_bib20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynj\u00e4l\u00e4","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213902_bib21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1136\/annrheumdis-2018-213902_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-015-0912-y","article-title":"Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)","volume":"18","author":"Heimans","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2018-213902_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7326\/M15-0919","article-title":"Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial","volume":"164","author":"Markusse","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1136\/annrheumdis-2018-213902_bib24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213902_bib25","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213902_bib26","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213902_bib27","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/art.34373","article-title":"Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score","volume":"64","author":"Consolaro","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213902_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213902_bib29","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.1780371209","article-title":"Measurement of health status in children with juvenile rheumatoid arthritis","volume":"37","author":"Singh","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213902_bib30","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2018-213902_bib31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group","volume":"326","author":"Giannini","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2018-213902_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5455\/apr.091520140648","article-title":"Polyarteritis nodosa mimicking juvenile idiopathic arthritis: A case report","volume":"3","author":"Muller","year":"2014","journal-title":"Ann Paediatr Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213902_bib33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/acr.22259","article-title":"Childhood arthritis and rheumatology research alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis","volume":"66","author":"Ringold","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2018-213902_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12969-017-0138-4","article-title":"A comparison of three treatment strategies in recent onset non-systemic juvenile idiopathic arthritis: Initial 3-months results of the best for kids-study","volume":"15","author":"Hissink Muller","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1136\/annrheumdis-2018-213902_bib35","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","article-title":"The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort","volume":"74","author":"Guzman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213902_bib36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","article-title":"The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort","volume":"75","author":"Guzman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-213902_bib37","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.40509","article-title":"Risk, timing, and predictors of disease flare after discontinuation of anti-tumor necrosis factor therapy in children with polyarticular forms of juvenile idiopathic arthritis with clinically inactive disease","volume":"70","author":"Lovell","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213902_bib38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/acr.20069","article-title":"Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis","volume":"62","author":"Albers","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2018-213902_bib39","first-page":"972","article-title":"Two-year outcome of juvenile idiopathic arthritis in current daily practice: what can we tell our patients?","volume":"30","author":"Anink","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2018-213902_bib40","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/rheumatology\/kew021","article-title":"Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children and young people with Juvenile Idiopathic Arthritis: results from the childhood arthritis prospective Study","volume":"55","author":"McErlane","year":"2016","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2018-213902_bib41","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/rheumatology\/keu457","article-title":"Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting","volume":"54","author":"Tarkiainen","year":"2015","journal-title":"Rheumatology"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724008252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724008252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2018-213902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T23:43:19Z","timestamp":1737330199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724008252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0003496724008252"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2018-213902","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734217367.793582494","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2018-213902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 \u00a9 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}